Johnson & Johnson to Pay $2.2 Billion for Unapproved Drug Promotions

Pushing medications for unauthorized uses

Johnson & Johnson and its subsidiaries have agreed to pay over $2.2 billion to resolve criminal and civil allegations of promoting three prescription drugs for off-label uses not approved by the Food and Drug Administration, the Department of Justice announced on Monday.

The allegations include paying kickbacks to physicians and pharmacies to recommend and prescribe Risperdal and Invega, both antipsychotic drugs, and Natrecor, which is used to treat heart failure.

The figure includes $1.72 billion in civil settlements with federal and state governments as well as $485 million in criminal fines and forfeited profits.

Comments

[Killazontherun]

Thank God for those men and women of the FDA adamantly working on our behalf to make sure no opinion of medical product viability they haven't sanctioned gets out there a decade or two before they deem it worthy. A generation or two of patients who would otherwise benefit will be sacrificed first, but its for the Greater Good that the evil profit motive is kept in in check.

[Sevo]

...Congress shall make no law, unless the Fed can profit by....